Cargando…

Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1)

Low-dose metronomic (LDM) chemotherapy is an alternative to conventional chemotherapy and is the most frequently used approach in low dose chemotherapy regimens. The selection of patients, drug dosages, and dosing intervals in LDM is empirical. In this study, we systematically examined the schedule-...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosero, Gustavo, Pattarone, Gisela, Peñaherera, Ana, Pilz, Julia, Bödecker, Joschka, Perez, Maximiliano, Mertelsmann, Roland, Lerner, Betiana, Follo, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522273/
https://www.ncbi.nlm.nih.gov/pubmed/36174026
http://dx.doi.org/10.1371/journal.pone.0274911
_version_ 1784800028192145408
author Rosero, Gustavo
Pattarone, Gisela
Peñaherera, Ana
Pilz, Julia
Bödecker, Joschka
Perez, Maximiliano
Mertelsmann, Roland
Lerner, Betiana
Follo, Marie
author_facet Rosero, Gustavo
Pattarone, Gisela
Peñaherera, Ana
Pilz, Julia
Bödecker, Joschka
Perez, Maximiliano
Mertelsmann, Roland
Lerner, Betiana
Follo, Marie
author_sort Rosero, Gustavo
collection PubMed
description Low-dose metronomic (LDM) chemotherapy is an alternative to conventional chemotherapy and is the most frequently used approach in low dose chemotherapy regimens. The selection of patients, drug dosages, and dosing intervals in LDM is empirical. In this study, we systematically examined the schedule-dependent interaction of drugs on a breast cancer cell line (BCC) cultured in chambered coverslips. The LDM studies were combined with cell staining in order to better characterize different cell states and cell death modes, including caspase-dependent apoptosis, caspase-independent cell death and autophagy-dependent cell death. Microscope images were examined using the Fiji Trainable Weka Segmentation plugin to analyse cell area in 7500 images showing different modes of cell death. Paclitaxel combined with LDM chemotherapy demonstrated a reduction in the area covered by live cells. In contrast, there was an induction of high levels of cell death due to caspase-dependent apoptosis.
format Online
Article
Text
id pubmed-9522273
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-95222732022-09-30 Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1) Rosero, Gustavo Pattarone, Gisela Peñaherera, Ana Pilz, Julia Bödecker, Joschka Perez, Maximiliano Mertelsmann, Roland Lerner, Betiana Follo, Marie PLoS One Research Article Low-dose metronomic (LDM) chemotherapy is an alternative to conventional chemotherapy and is the most frequently used approach in low dose chemotherapy regimens. The selection of patients, drug dosages, and dosing intervals in LDM is empirical. In this study, we systematically examined the schedule-dependent interaction of drugs on a breast cancer cell line (BCC) cultured in chambered coverslips. The LDM studies were combined with cell staining in order to better characterize different cell states and cell death modes, including caspase-dependent apoptosis, caspase-independent cell death and autophagy-dependent cell death. Microscope images were examined using the Fiji Trainable Weka Segmentation plugin to analyse cell area in 7500 images showing different modes of cell death. Paclitaxel combined with LDM chemotherapy demonstrated a reduction in the area covered by live cells. In contrast, there was an induction of high levels of cell death due to caspase-dependent apoptosis. Public Library of Science 2022-09-29 /pmc/articles/PMC9522273/ /pubmed/36174026 http://dx.doi.org/10.1371/journal.pone.0274911 Text en © 2022 Rosero et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rosero, Gustavo
Pattarone, Gisela
Peñaherera, Ana
Pilz, Julia
Bödecker, Joschka
Perez, Maximiliano
Mertelsmann, Roland
Lerner, Betiana
Follo, Marie
Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1)
title Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1)
title_full Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1)
title_fullStr Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1)
title_full_unstemmed Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1)
title_short Metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (JIMT-1)
title_sort metronomic doses and drug schematic combination response tested within chambered coverslips for the treatment of breast cancer cells (jimt-1)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522273/
https://www.ncbi.nlm.nih.gov/pubmed/36174026
http://dx.doi.org/10.1371/journal.pone.0274911
work_keys_str_mv AT roserogustavo metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1
AT pattaronegisela metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1
AT penahereraana metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1
AT pilzjulia metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1
AT bodeckerjoschka metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1
AT perezmaximiliano metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1
AT mertelsmannroland metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1
AT lernerbetiana metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1
AT follomarie metronomicdosesanddrugschematiccombinationresponsetestedwithinchamberedcoverslipsforthetreatmentofbreastcancercellsjimt1